Prevention and treatment for microbial infections
The present invention features a composition comprising zinc pyrithione and silver sulfiadizine, a formulation thereof and a method of treating microbial infection using the composition.
1. A composition comprising zinc pyrithione and silver sulfadiazine wherein the weight ratio between zinc pyrithione and silver sulfadiazine is from 1:4 to 1:2, wherein the total concentration of silver sulfadiazine is 1 wt. %, and wherein the total concentration of zinc pyrithione is from 0.25 wt. % to 0.5 wt. %.
2. The composition of claim 1 , wherein the composition is for topical administration to a subject.
3. The composition of claim 2 , wherein the subject has microbial infection.
4. The composition of claim 3 , wherein the microbial infection is bacterial infection.
5. The composition of claim 1 , wherein the weight ratio between zinc pyrithione and silver sulfadiazine is 1:4.
6. The composition of claim 1 , wherein the weight ratio between zinc pyrithione and silver sulfadiazine is 1:2.
7. A topical formulation comprising zinc pyrithione, silver sulfadiazine, and one or more pharmaceutically acceptable carriers or excipients wherein the weight ratio between zinc pyrithione and silver sulfadiazine is from 1:4 to 1:2, wherein the total concentration of silver sulfadiazine is 1 wt. %, and wherein the total concentration of zinc pyrithione is from 0.25 wt. % to 0.5 wt. %.
8. The topical formulation of claim 7 , wherein the formulation is in the form of a cream, a lotion, an ointment, a hydrogel, a colloid, a gel, a foam, an oil, a milk, a suspension, a wipe, a sponge, a solution, an emulsion, a paste, a patch, a pladget, a swab, a dressing, a spray and a pad.
9. A method of decolonizing a microbial organism comprising contacting the microbial organism with a composition according to claim 1 wherein the microbial organism is Acinetobacter baumannii, Pseudomonas aeruginosa or Staphylococcus aureus.
10. A method of destroying or disrupting or inhibiting or reducing biofilm formation of a microbial organism comprising contacting the microbial organism with a composition according to claim 1 wherein the microbial organism is Acinetobacter baumannii, Staphylococcus aureus or Pseudomonas aeruginosa.
11. A method of treating a microbial infection in a subject comprising administering to the subject a therapeutically effective amount of the composition of claim 1 wherein the infection is Acinetobacter baumannii, Staphylococcus aureus or Pseudomonas aeruginosa.
12. The method of claim 11 , wherein the bacterial infection is characterized by colonization of a bacterium.
13. The method of claim 11 , wherein the bacterial infection is characterized by biofilm formation.
14. The method of claim 11 , wherein the microbial infection is a topical infection.
15. The method of claim 14 , wherein the topical infection is selected from wound, ulcer and lesion.
16. The composition of claim 4 , wherein the bacterial infection is a gram-negative or gram-positive bacterial infection.
17. The composition of claim 4 , wherein the bacterial infection is an Acinetobacter baumannii, Pseudomonas aeruginosa or Staphylococcus aureus infection.
18. The topical formulation of claim 7 , wherein the formulation is for administration to a subject with a gram-negative or gram-positive bacterial infection.
19. The topical formulation of claim 7 , wherein the formulation is for administration to a subject with an Acinetobacter baumannii, Pseudomonas aeruginosa or Staphylococcus aureus infection.